Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
Shattuck Labs shares rose about 4.8% on Friday, closing near $7.43. The move followed an inaugural note from JPMorgan’s Brian Cheng, who rated STTK overweight and set a $10 price target. The note cited Shattuck’s lead IBD drug candidate SL-325, referencing recent healthy volunteer data on safety and target engagement.
How this was made
The 30-second read
Why it matters
The article attributes the nearly 5% Friday gain to a new JPMorgan analyst note that initiated coverage as overweight with a $10 price target, emphasizing volunteer data on safety and target engagement for SL-325.
Market read
A same-day initiation with a large upside target can drive short-term momentum in small-cap biotech, especially when it highlights lead-asset data quality.
What to watch
Phase 2 entry is still future (Q3 per the article), so traders may need confirmation from subsequent trial updates; also, the stock’s prior run-up risk remains high in microcap biotech.
Background
Shattuck Labs is a clinical-stage biotech developing SL-325 for inflammatory bowel disease, with Phase 2 planned for Q3.
Ticker impact
J.P. Morgan’s inaugural note rated Shattuck Labs overweight and set a $10 target, citing SL-325 safety and target engagement data.
Likely supports continued upside bias for STTK over the next several sessions, but follow-through depends on upcoming Phase 2 timing and additional clinical/regulatory updates.
The article’s newest concrete catalyst is the same-day analyst initiation and target change, which can drive momentum in small-cap biotech; however, it is not new clinical or regulatory data from the company itself.
Market effects
Reinforces risk-on sentiment for clinical-stage IBD biotech names when analyst notes highlight cleaner safety and engagement for lead assets.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited, as the catalyst is company-specific analyst coverage rather than a global biotech/regulatory development.
Counterpoint
The rally may fade because the catalyst is an analyst initiation, not new company-reported trial results or regulatory progress.
Key entities
- companyShattuck Labs
Clinical-stage biotech whose shares rose nearly 5% on Friday after JPMorgan initiated coverage.
- drug_candidateSL-325
Lead antagonist antibody candidate for inflammatory bowel disease discussed as having cleaner safety and stronger target engagement.
- analystBrian Cheng (JPMorgan)
Published the inaugural take rating STTK overweight and set a $10 price target.
